Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 195 entries
Sorted by: Best Match Show Resources per page
Targeting the Wnt/β-catenin pathway in human osteosarcoma cells.

Oncotarget

Fang F, VanCleave A, Helmuth R, Torres H, Rickel K, Wollenzien H, Sun H, Zeng E, Zhao J, Tao J.
PMID: 30613366
Oncotarget. 2018 Dec 04;9(95):36780-36792. doi: 10.18632/oncotarget.26377. eCollection 2018 Dec 04.

Aberrant activation of Wnt signaling has been implicated in human osteosarcoma, which may provide a genetic vulnerability that can be targeted in osteosarcoma treatment. To test whether Wnt activation is necessary for osteosarcoma growth, colony formation, invasion, and metastasis,...

Cite
Fang F, VanCleave A, Helmuth R, et al. Targeting the Wnt/β-catenin pathway in human osteosarcoma cells. Oncotarget. 2018;9(95):36780-36792doi: 10.18632/oncotarget.26377.
Fang, F., VanCleave, A., Helmuth, R., Torres, H., Rickel, K., Wollenzien, H., Sun, H., Zeng, E., Zhao, J., & Tao, J. (2018). Targeting the Wnt/β-catenin pathway in human osteosarcoma cells. Oncotarget, 9(95), 36780-36792. https://doi.org/10.18632/oncotarget.26377
Fang, Fang, et al. "Targeting the Wnt/β-catenin pathway in human osteosarcoma cells." Oncotarget vol. 9,95 (2018): 36780-36792. doi: https://doi.org/10.18632/oncotarget.26377
Fang F, VanCleave A, Helmuth R, Torres H, Rickel K, Wollenzien H, Sun H, Zeng E, Zhao J, Tao J. Targeting the Wnt/β-catenin pathway in human osteosarcoma cells. Oncotarget. 2018 Dec 04;9(95):36780-36792. doi: 10.18632/oncotarget.26377. eCollection 2018 Dec 04. PMID: 30613366; PMCID: PMC6298399.
Copy Download .nbib Format: NLM
Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study.

JMIR mHealth and uHealth

Reddy RK, Pooni R, Zaharieva DP, Senf B, El Youssef J, Dassau E, Doyle Iii FJ, Clements MA, Rickels MR, Patton SR, Castle JR, Riddell MC, Jacobs PG.
PMID: 30530451
JMIR Mhealth Uhealth. 2018 Dec 10;6(12):e10338. doi: 10.2196/10338.

BACKGROUND: Wrist-worn activity monitors are often used to monitor heart rate (HR) and energy expenditure (EE) in a variety of settings including more recently in medical applications. The use of real-time physiological signals to inform medical systems including drug...

Cite
Reddy RK, Pooni R, Zaharieva DP, et al. Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study. JMIR Mhealth Uhealth. 2018;6(12):e10338doi: 10.2196/10338.
Reddy, R. K., Pooni, R., Zaharieva, D. P., Senf, B., El Youssef, J., Dassau, E., Doyle Iii, F. J., Clements, M. A., Rickels, M. R., Patton, S. R., Castle, J. R., Riddell, M. C., & Jacobs, P. G. (2018). Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study. JMIR mHealth and uHealth, 6(12), e10338. https://doi.org/10.2196/10338
Reddy, Ravi Kondama, et al. "Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study." JMIR mHealth and uHealth vol. 6,12 (2018): e10338. doi: https://doi.org/10.2196/10338
Reddy RK, Pooni R, Zaharieva DP, Senf B, El Youssef J, Dassau E, Doyle Iii FJ, Clements MA, Rickels MR, Patton SR, Castle JR, Riddell MC, Jacobs PG. Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study. JMIR Mhealth Uhealth. 2018 Dec 10;6(12):e10338. doi: 10.2196/10338. PMID: 30530451; PMCID: PMC6305876.
Copy Download .nbib Format: NLM
Macrophage-targeted therapy unlocks antitumoral crosstalk between IFN.

Cancer immunology research

Pfirschke C, Zilionis R, Engblom C, Messemaker M, Zou AE, Rickelt S, Gort-Freitas NA, Lin Y, Bill R, Siwicki M, Gungabeesoon J, Sprachman MM, Marquard AN, Rodell CB, Cuccarese MF, Quintana J, Ahmed MS, Kohler RH, Savova V, Weissleder R, Klein AM, Pittet MJ.
PMID: 34795032
Cancer Immunol Res. 2021 Nov 18; doi: 10.1158/2326-6066.CIR-21-0326. Epub 2021 Nov 18.

Macrophages often abound within tumors, express colony-stimulating factor 1 receptor (CSF1R), and are linked to adverse patient survival. Drugs blocking CSF1R signaling have been used to suppress tumor-promoting macrophage responses; however, their mechanisms of action remain incompletely understood. Here,...

Cite
Pfirschke C, Zilionis R, Engblom C, et al. Macrophage-targeted therapy unlocks antitumoral crosstalk between IFN. Cancer Immunol Res. 2021;doi: 10.1158/2326-6066.CIR-21-0326.
Pfirschke, C., Zilionis, R., Engblom, C., Messemaker, M., Zou, A. E., Rickelt, S., Gort-Freitas, N. A., Lin, Y., Bill, R., Siwicki, M., Gungabeesoon, J., Sprachman, M. M., Marquard, A. N., Rodell, C. B., Cuccarese, M. F., Quintana, J., Ahmed, M. S., Kohler, R. H., Savova, V., Weissleder, R., Klein, A. M., & Pittet, M. J. (2021). Macrophage-targeted therapy unlocks antitumoral crosstalk between IFN. Cancer immunology research, . https://doi.org/10.1158/2326-6066.CIR-21-0326
Pfirschke, Christina, et al. "Macrophage-targeted therapy unlocks antitumoral crosstalk between IFN." Cancer immunology research vol. (2021). doi: https://doi.org/10.1158/2326-6066.CIR-21-0326
Pfirschke C, Zilionis R, Engblom C, Messemaker M, Zou AE, Rickelt S, Gort-Freitas NA, Lin Y, Bill R, Siwicki M, Gungabeesoon J, Sprachman MM, Marquard AN, Rodell CB, Cuccarese MF, Quintana J, Ahmed MS, Kohler RH, Savova V, Weissleder R, Klein AM, Pittet MJ. Macrophage-targeted therapy unlocks antitumoral crosstalk between IFN. Cancer Immunol Res. 2021 Nov 18; doi: 10.1158/2326-6066.CIR-21-0326. Epub 2021 Nov 18. PMID: 34795032.
Copy Download .nbib Format: NLM
Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop.

Toxins

Hefter H, Nickels W, Rosenthal D, Samadzadeh S, Albrecht P.
PMID: 34357938
Toxins (Basel). 2021 Jul 02;13(7). doi: 10.3390/toxins13070466.

The objective of this study was to quantify the increase in efficacy during the first four cycles of treatment with botulinum toxin type/A (BoNT/A) in 24 free-walking BoNT/A naïve adult patients with post-stroke hemispasticity and spastic foot drop. Patients...

Cite
Hefter H, Nickels W, Rosenthal D, et al. Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop. Toxins (Basel). 2021;13(7)doi: 10.3390/toxins13070466.
Hefter, H., Nickels, W., Rosenthal, D., Samadzadeh, S., & Albrecht, P. (2021). Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop. Toxins, 13(7), . https://doi.org/10.3390/toxins13070466
Hefter, Harald, et al. "Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop." Toxins vol. 13,7 (2021). doi: https://doi.org/10.3390/toxins13070466
Hefter H, Nickels W, Rosenthal D, Samadzadeh S, Albrecht P. Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop. Toxins (Basel). 2021 Jul 02;13(7). doi: 10.3390/toxins13070466. PMID: 34357938; PMCID: PMC8310361.
Copy Download .nbib Format: NLM
Myocardial Perfusion in Hypoplastic Left Heart Syndrome.

Circulation. Cardiovascular imaging

Rickers C, Wegner P, Silberbach M, Madriago E, Gabbert DD, Kheradvar A, Voges I, Scheewe J, Attmann T, Jerosch-Herold M, Kramer HH.
PMID: 34610753
Circ Cardiovasc Imaging. 2021 Oct;14(10):e012468. doi: 10.1161/CIRCIMAGING.121.012468. Epub 2021 Oct 06.

BACKGROUND: The status of the systemic right ventricular coronary microcirculation in hypoplastic left heart syndrome (HLHS) is largely unknown. It is presumed that the systemic right ventricle's coronary microcirculation exhibits unique pathophysiological characteristics of HLHS in Fontan circulation. The...

Cite
Rickers C, Wegner P, Silberbach M, et al. Myocardial Perfusion in Hypoplastic Left Heart Syndrome. Circ Cardiovasc Imaging. 2021;14(10):e012468doi: 10.1161/CIRCIMAGING.121.012468.
Rickers, C., Wegner, P., Silberbach, M., Madriago, E., Gabbert, D. D., Kheradvar, A., Voges, I., Scheewe, J., Attmann, T., Jerosch-Herold, M., & Kramer, H. H. (2021). Myocardial Perfusion in Hypoplastic Left Heart Syndrome. Circulation. Cardiovascular imaging, 14(10), e012468. https://doi.org/10.1161/CIRCIMAGING.121.012468
Rickers, Carsten, et al. "Myocardial Perfusion in Hypoplastic Left Heart Syndrome." Circulation. Cardiovascular imaging vol. 14,10 (2021): e012468. doi: https://doi.org/10.1161/CIRCIMAGING.121.012468
Rickers C, Wegner P, Silberbach M, Madriago E, Gabbert DD, Kheradvar A, Voges I, Scheewe J, Attmann T, Jerosch-Herold M, Kramer HH. Myocardial Perfusion in Hypoplastic Left Heart Syndrome. Circ Cardiovasc Imaging. 2021 Oct;14(10):e012468. doi: 10.1161/CIRCIMAGING.121.012468. Epub 2021 Oct 06. PMID: 34610753.
Copy Download .nbib Format: NLM
Call for autistic vets to participate in study.

The Veterinary record

Pickles K.
PMID: 34994413
Vet Rec. 2022 Jan;190(1):40. doi: 10.1002/vetr.1354.

No abstract available.

Cite
Pickles K. Call for autistic vets to participate in study. Vet Rec. 2022;190(1):40doi: 10.1002/vetr.1354.
Pickles, K. (2022). Call for autistic vets to participate in study. The Veterinary record, 190(1), 40. https://doi.org/10.1002/vetr.1354
Pickles, Kirstie. "Call for autistic vets to participate in study." The Veterinary record vol. 190,1 (2022): 40. doi: https://doi.org/10.1002/vetr.1354
Pickles K. Call for autistic vets to participate in study. Vet Rec. 2022 Jan;190(1):40. doi: 10.1002/vetr.1354. PMID: 34994413.
Copy Download .nbib Format: NLM
Coating-relevant properties of high-index optical polymers for automotive applications.

Applied optics

Schulz U, Gratzke N, Rickelt F, Hahmann C, Seifert T, Gärtner A.
PMID: 34263791
Appl Opt. 2021 Jul 10;60(20):E34-E40. doi: 10.1364/AO.422878.

High-transparent polymers exhibiting a refractive index beyond 1.6 enhance the available range of optical plastics. The aim of this study is to evaluate optical polyesters (OKP-1 and OKP-4) and special new polycarbonates (PCs) (EP-6000 and EP-8000) in comparison with...

Cite
Schulz U, Gratzke N, Rickelt F, et al. Coating-relevant properties of high-index optical polymers for automotive applications. Appl Opt. 2021;60(20):E34-E40doi: 10.1364/AO.422878.
Schulz, U., Gratzke, N., Rickelt, F., Hahmann, C., Seifert, T., & Gärtner, A. (2021). Coating-relevant properties of high-index optical polymers for automotive applications. Applied optics, 60(20), E34-E40. https://doi.org/10.1364/AO.422878
Schulz, Ulrike, et al. "Coating-relevant properties of high-index optical polymers for automotive applications." Applied optics vol. 60,20 (2021): E34-E40. doi: https://doi.org/10.1364/AO.422878
Schulz U, Gratzke N, Rickelt F, Hahmann C, Seifert T, Gärtner A. Coating-relevant properties of high-index optical polymers for automotive applications. Appl Opt. 2021 Jul 10;60(20):E34-E40. doi: 10.1364/AO.422878. PMID: 34263791.
Copy Download .nbib Format: NLM
A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.

Breast cancer research : BCR

Ibrahim AM, Bilsland A, Rickelt S, Morris JS, Stein T.
PMID: 34565423
Breast Cancer Res. 2021 Sep 26;23(1):90. doi: 10.1186/s13058-021-01470-3.

BACKGROUND: During pregnancy, the mouse mammary ductal epithelium branches and grows into the surrounding stroma, requiring extensive extracellular matrix (ECM) and tissue remodelling. It therefore shows parallels to cancer invasion. We hypothesised that similar molecular mechanisms may be utilised...

Cite
Ibrahim AM, Bilsland A, Rickelt S, et al. A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans. Breast Cancer Res. 2021;23(1):90doi: 10.1186/s13058-021-01470-3.
Ibrahim, A. M., Bilsland, A., Rickelt, S., Morris, J. S., & Stein, T. (2021). A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans. Breast cancer research : BCR, 23(1), 90. https://doi.org/10.1186/s13058-021-01470-3
Ibrahim, Ayman M, et al. "A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans." Breast cancer research : BCR vol. 23,1 (2021): 90. doi: https://doi.org/10.1186/s13058-021-01470-3
Ibrahim AM, Bilsland A, Rickelt S, Morris JS, Stein T. A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans. Breast Cancer Res. 2021 Sep 26;23(1):90. doi: 10.1186/s13058-021-01470-3. PMID: 34565423; PMCID: PMC8474794.
Copy Download .nbib Format: NLM
Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells.

Cancer immunology research

Pfirschke C, Zilionis R, Engblom C, Messemaker M, Zou AE, Rickelt S, Gort-Freitas NA, Lin Y, Bill R, Siwicki M, Gungabeesoon J, Sprachman MM, Marquard AN, Rodell CB, Cuccarese MF, Quintana J, Ahmed MS, Kohler RH, Savova V, Weissleder R, Klein AM, Pittet MJ.
PMID: 34795032
Cancer Immunol Res. 2021 Dec 01; doi: 10.1158/2326-6066.CIR-21-0326. Epub 2021 Dec 01.

Macrophages often abound within tumors, express colony-stimulating factor 1 receptor (CSF1R), and are linked to adverse patient survival. Drugs blocking CSF1R signaling have been used to suppress tumor-promoting macrophage responses; however, their mechanisms of action remain incompletely understood. Here,...

Cite
Pfirschke C, Zilionis R, Engblom C, et al. Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells. Cancer Immunol Res. 2021;doi: 10.1158/2326-6066.CIR-21-0326.
Pfirschke, C., Zilionis, R., Engblom, C., Messemaker, M., Zou, A. E., Rickelt, S., Gort-Freitas, N. A., Lin, Y., Bill, R., Siwicki, M., Gungabeesoon, J., Sprachman, M. M., Marquard, A. N., Rodell, C. B., Cuccarese, M. F., Quintana, J., Ahmed, M. S., Kohler, R. H., Savova, V., Weissleder, R., Klein, A. M., & Pittet, M. J. (2021). Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells. Cancer immunology research, . https://doi.org/10.1158/2326-6066.CIR-21-0326
Pfirschke, Christina, et al. "Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells." Cancer immunology research vol. (2021). doi: https://doi.org/10.1158/2326-6066.CIR-21-0326
Pfirschke C, Zilionis R, Engblom C, Messemaker M, Zou AE, Rickelt S, Gort-Freitas NA, Lin Y, Bill R, Siwicki M, Gungabeesoon J, Sprachman MM, Marquard AN, Rodell CB, Cuccarese MF, Quintana J, Ahmed MS, Kohler RH, Savova V, Weissleder R, Klein AM, Pittet MJ. Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells. Cancer Immunol Res. 2021 Dec 01; doi: 10.1158/2326-6066.CIR-21-0326. Epub 2021 Dec 01. PMID: 34795032.
Copy Download .nbib Format: NLM
Five-year cumulative incidence and progression of age-related macular degeneration: results from the German population-based Gutenberg Health Study (GHS).

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Korb CA, Elbaz H, Schuster AK, Nickels S, Ponto KA, Schulz A, Wild PS, Münzel T, Beutel ME, Schmidtmann I, Lackner KJ, Peto T, Pfeiffer N.
PMID: 34424371
Graefes Arch Clin Exp Ophthalmol. 2022 Jan;260(1):55-64. doi: 10.1007/s00417-021-05312-y. Epub 2021 Aug 23.

PURPOSE: Age-related macular degeneration (AMD) is a major cause of visual impairment and blindness. This study evaluates the incidence and progression of AMD in a large German cohort.METHODS: The Gutenberg Health Study (GHS) is a population-based, prospective, observational cohort...

Cite
Korb CA, Elbaz H, Schuster AK, et al. Five-year cumulative incidence and progression of age-related macular degeneration: results from the German population-based Gutenberg Health Study (GHS). Graefes Arch Clin Exp Ophthalmol. 2021;260(1):55-64doi: 10.1007/s00417-021-05312-y.
Korb, C. A., Elbaz, H., Schuster, A. K., Nickels, S., Ponto, K. A., Schulz, A., Wild, P. S., Münzel, T., Beutel, M. E., Schmidtmann, I., Lackner, K. J., Peto, T., & Pfeiffer, N. (2022). Five-year cumulative incidence and progression of age-related macular degeneration: results from the German population-based Gutenberg Health Study (GHS). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 260(1), 55-64. https://doi.org/10.1007/s00417-021-05312-y
Korb, Christina A, et al. "Five-year cumulative incidence and progression of age-related macular degeneration: results from the German population-based Gutenberg Health Study (GHS)." Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie vol. 260,1 (2022): 55-64. doi: https://doi.org/10.1007/s00417-021-05312-y
Korb CA, Elbaz H, Schuster AK, Nickels S, Ponto KA, Schulz A, Wild PS, Münzel T, Beutel ME, Schmidtmann I, Lackner KJ, Peto T, Pfeiffer N. Five-year cumulative incidence and progression of age-related macular degeneration: results from the German population-based Gutenberg Health Study (GHS). Graefes Arch Clin Exp Ophthalmol. 2022 Jan;260(1):55-64. doi: 10.1007/s00417-021-05312-y. Epub 2021 Aug 23. PMID: 34424371.
Copy Download .nbib Format: NLM
207.3: Predictive Value of C-peptide Measures for Clinical Outcomes of Islet Transplantation in Type 1 Diabetes: A Report From the Collaborative Islet Transplant Registry (CITR).

Transplantation

Baidal D, Rickels M, Ballou C, Payne E, Barton F, Alejandro R.
PMID: 34908300
Transplantation. 2021 Dec 01;105(12):S4. doi: 10.1097/01.tp.0000804292.89124.7f.

No abstract available.

Cite
Baidal D, Rickels M, Ballou C, et al. 207.3: Predictive Value of C-peptide Measures for Clinical Outcomes of Islet Transplantation in Type 1 Diabetes: A Report From the Collaborative Islet Transplant Registry (CITR). Transplantation. 2021;105(12):S4doi: 10.1097/01.tp.0000804292.89124.7f.
Baidal, D., Rickels, M., Ballou, C., Payne, E., Barton, F., & Alejandro, R. (2021). 207.3: Predictive Value of C-peptide Measures for Clinical Outcomes of Islet Transplantation in Type 1 Diabetes: A Report From the Collaborative Islet Transplant Registry (CITR). Transplantation, 105(12), S4. https://doi.org/10.1097/01.tp.0000804292.89124.7f
Baidal, David, et al. "207.3: Predictive Value of C-peptide Measures for Clinical Outcomes of Islet Transplantation in Type 1 Diabetes: A Report From the Collaborative Islet Transplant Registry (CITR)." Transplantation vol. 105,12 (2021): S4. doi: https://doi.org/10.1097/01.tp.0000804292.89124.7f
Baidal D, Rickels M, Ballou C, Payne E, Barton F, Alejandro R. 207.3: Predictive Value of C-peptide Measures for Clinical Outcomes of Islet Transplantation in Type 1 Diabetes: A Report From the Collaborative Islet Transplant Registry (CITR). Transplantation. 2021 Dec 01;105(12):S4. doi: 10.1097/01.tp.0000804292.89124.7f. PMID: 34908300.
Copy Download .nbib Format: NLM
306.1: Clinical Metrics Predict Defective Physiologic Responses to Hypoglycemia in Long-standing Type 1 Diabetes and May Facilitate Early Consideration of Referral for Beta-Cell Replacement Therapy.

Transplantation

Flatt A, Chen E, Peleckis AJ, Dalton-Bakes C, Nguyen HL, Gallop R, Rickels MR.
PMID: 34908320
Transplantation. 2021 Dec 01;105(12):S18. doi: 10.1097/01.tp.0000804372.45039.8e.

No abstract available.

Cite
Flatt A, Chen E, Peleckis AJ, et al. 306.1: Clinical Metrics Predict Defective Physiologic Responses to Hypoglycemia in Long-standing Type 1 Diabetes and May Facilitate Early Consideration of Referral for Beta-Cell Replacement Therapy. Transplantation. 2021;105(12):S18doi: 10.1097/01.tp.0000804372.45039.8e.
Flatt, A., Chen, E., Peleckis, A. J., Dalton-Bakes, C., Nguyen, H. L., Gallop, R., & Rickels, M. R. (2021). 306.1: Clinical Metrics Predict Defective Physiologic Responses to Hypoglycemia in Long-standing Type 1 Diabetes and May Facilitate Early Consideration of Referral for Beta-Cell Replacement Therapy. Transplantation, 105(12), S18. https://doi.org/10.1097/01.tp.0000804372.45039.8e
Flatt, Anneliese, et al. "306.1: Clinical Metrics Predict Defective Physiologic Responses to Hypoglycemia in Long-standing Type 1 Diabetes and May Facilitate Early Consideration of Referral for Beta-Cell Replacement Therapy." Transplantation vol. 105,12 (2021): S18. doi: https://doi.org/10.1097/01.tp.0000804372.45039.8e
Flatt A, Chen E, Peleckis AJ, Dalton-Bakes C, Nguyen HL, Gallop R, Rickels MR. 306.1: Clinical Metrics Predict Defective Physiologic Responses to Hypoglycemia in Long-standing Type 1 Diabetes and May Facilitate Early Consideration of Referral for Beta-Cell Replacement Therapy. Transplantation. 2021 Dec 01;105(12):S18. doi: 10.1097/01.tp.0000804372.45039.8e. PMID: 34908320.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 195 entries